



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
Rockville MD 20857

February 21, 2007

FILE COPY

Kip Vought
Regulus Pharmaceutical Consulting, Inc.
4840 Pearl East Circle Suite 201E
Boulder, Colorado 80301

Dear Mr. Vought:

Your petition requesting the Food and Drug Administration to determine whether a previously listed drug Eloxatin (oxaliplatin for injection) Lyophilized Powder for Infusion, 50 and 100 mg vials has been voluntarily withdrawn from sale for safety or efficacy reasons, and to Accept an ANDA for a Generic Version of the Durg, was received by this office on 02/21/2007. It was assigned docket number 2007P-0062/CP1 and it was filed on 02/21/2007. Please refer to this docket number in future correspondence on this subject with the Agency.

Please note that the acceptance of the petition for filing is a procedural matter in that it in no way reflects an agency decision on the substantive merits of the petition.

Sincerely,

A handwritten signature in cursive script that reads "Gloria Ortega".

Gloria Ortega
Division of Dockets Management
Office of Management Programs
Office of Management

2007 P- 006 2

ACK 1